| Ytd | 97.37% | |
| 1y | -48.56% |
| Open | 3.76 | Prev Close | 3.81 | Low | 3.75 | High | 3.76 | Mkt Cap | 1.71M |
| Vol | 880.00 | Avg Vol | 54.75K | EPS | -5.55 | P/E | -0.69 | Forward P/E | N/A |
| Beta | 0.93 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 3.51 | 200-d Avg | 4.47 | 1yr Est | 0.00 |
NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company devel
Laidlaw & Co. analyst Yale Jen initiates coverage on NewcelX (NASDAQ:NCEL) with a Buy rating
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-